Lancet: Procylovir is used to stop mother-to-child transmission of the cytocytovirus in the early stages of pregnancy.

Cytovirus infection is a common congenital infection, the incidence of progeny after primary maternal infection is high, there is no effective way to prevent mother-to-child transmission of the virus.
recently looked at the effects of pyrethrovirus in preventing primary mother infections from spreading vertically to the fetus in the early stages of pregnancy.
the prospective, randomized, double-blind, placebo-controlled trial was conducted at the Feto-Maternal Clinic in Israel.
pregnant women aged 18 or over who were diagnosed with primary cytokine virus infection before or three months of pregnancy, patients were randomly treated with psilovir (8 grams per day, twice a day) or placebo, followed by amniotic membrane puncture 21-22 weeks after pregnancy.
end of this study is the vertical propagation rate of cytocytovirus.
90 patients were involved in the study, including 45 patients in the psilocybe group (all single births) and 45 patients in the placebo group (43 listed fetuses and 2 pairs of twins).
In the psilocybe group, 5 (11%) of patients tested positive for fetal cytomevirus after amniotic membrane puncture, while 47 cases in the placebo group and 14 (30%) fetal positive after amniotic membrane puncture (the ratio of vertical transmission of cytomeral virus was 0.29).
patients with primary cytokine virus infection in the early stages of pregnancy, 2 cases of cytokine amniotic membrane puncture in the pyrethroid group tested positive, significantly lower than the 11 cases in the placebo group (11% vs 48%).
adverse events that had no clinical significance between the two groups.
study suggests that psilovirus can effectively prevent vertical transmission of the fetus after primary cytocytovirus infection in the mother in the early stages of pregnancy.
.